Pharmaceutical

Vasomune wins FDA fast track designation for lung condition treatment

Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the prevention and treatment of ARDS in pneumonia.

May 29, 2024 - 04:00
Vasomune wins FDA fast track designation for lung condition treatment
Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the prevention and treatment of ARDS in pneumonia.
Read the original article

Tags:

Previous Article

HKUST researchers enhance performance of eco-friendly cooling applications by de...

Next Article

Self-amplifying RNA and vaccine innovation: getting from concept to clinic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

What does Biden’s executive order mean for worldwide AI regulation?

What does Biden’s executive order mean for worldwide AI...

Nov 8, 2023

STAT+: Sophisticated phishing and deepfakes: How generative AI brings new threats for hospitals

STAT+: Sophisticated phishing and deepfakes: How genera...

Jan 30, 2024

STAT+: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do

STAT+: Congress’s PBM reforms won’t end America’s drug ...

Jul 26, 2023